Glaukos IPO Lockup Expiration Warrants Your Immediate Attention

Glaukos Corporation (NYSE:GKOS) – Sell or Short Recommendation – PT $21.75

December 22, 2015 concludes the 180-day lockup period on Glaukos Corporation.

We previewed this event for GKOS on our IPO Insights platform.

When the lockup period ends for GKOS, its pre-IPO shareholders, directors and executives will have the chance to sell their ~24 million shares. The potential for a sudden increase in stock available in the open market may cause a significant decrease in GKOS shares.

(click to enlarge)

(Source)

The event offers short sellers a new opportunity.

Business Summary: Ophthalmic Medical Technology Company Focused on Treatment of Glaucoma

Glaukos Corporation is an ophthalmic medical technology company that develops and commercializes products and procedures that treat glaucoma, which affects nearly 78 million people worldwide and is the second leading cause of blindness. Glaukos established Micro-Invasive Glaucoma Surgery (MIGS) and other leading devices and procedures.

The company’s portfolio includes a comprehensive and proprietary array of products such as the iStent, a micro-bypass stent used with cataract surgery; the iStent Inject Trabecular Micro-Bypass Stent for reducing intraocular pressure; the iStent Suprachoroidal Micro-Bypass Stent to reduce intraocular pressure through the suprachoroidal space of the eye; and iDose, an injectable drug delivery implant.

The company notes that the iStent is the smallest medical device ever approved by the FDA, and it was the first commercially available MIGS treatment solution. The iStent procedure that is used in conjunction with cataract surgery is reimbursable by Medicare and most commercial insurance companies. Glaukos has sold over 70,000 iStent devices through December 31, 2014.

Traditional treatments for glaucoma consist of using multiple types of prescription eye drops and in severe cases invasive eye surgery.

Glaukos markets its products directly in the United States and Germany through its sales team of approximately 55 professionals, and through distribution partners in Canada, Asia Pacific, and Europe.